Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Assets Current assets Cash and cash equivalents $ 63,212 $ 21,929 Accounts receivable 46,553 54,826 Net investment in leases 13,219 16,130 Inventories 20,315 23,124 Income taxes receivable 1,779 — Prepaid expenses and other current assets 4,480 3,754 Total current assets 149,558 119,763 Non-current assets Property and equipment, net 5,771 6,077 Right of use operating lease assets 20,041 21,322 Intangible assets, net 48,559 50,375 Goodwill 31,063 31,063 Accounts receivable, non-current 15,430 23,061 Other non-current assets 3,306 3,335 Total non-current assets 124,170 135,233 Total assets $ 273,728 $ 254,996 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 9,296 $ 9,984 Note payable 2,968 2,968 Earn-out, current 9,280 13,050 Accrued payroll and related taxes 13,80..."
08/07/2023 144 Form 144 - Report of proposed sale of securities:
07/28/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/18/2023 8-K Quarterly results
05/24/2023 SD Form SD - Specialized disclosure report:
05/12/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/08/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "First Quarter Revenue Increased 23% Year-Over-Year MINNEAPOLIS, MN, May 8, 2023 – Tactile Systems Technology, Inc. , a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary: ● Total revenue increased 23% year-over-year to $58.8 million ● Lymphedema products revenue increased 22% year-over-year ● Airway clearance products revenue increased 24% year-over-year ● Operating loss of $3.8 million versus $14.9 million in Q1 2022 ● Non-GAAP operating loss of $2.2 million versus $5.4 million in Q1 2022 ● Net loss of $1.9 million versus $15.6 million in Q1 2022 ● Adjusted EBITDA of $0.5 million versus a $2.6 million loss in Q1 20..."
03/27/2023 ARS Form ARS - Annual Report to Security Holders:
03/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Offer Letter between Elaine M. Birkemeyer and Tactile Systems Technology, Inc.",
"Tactile Medical Appoints Elaine Birkemeyer as Chief Financial Officer"
02/28/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between the Company and William Blair & Company, L.L.C., as the underwriter",
"Opinion of Faegre Drinker Biddle & Reath LLP",
"Tactile Systems Technology, Inc. Announces Proposed Public Offering of Common Stock MINNEAPOLIS, Minn.——Feb. 23, 2023— Tactile Systems Technology, Inc. , a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Tactile Medical intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the proposed offering will be sold by Tactile Medical. The offering is subject to market and other conditions, ...",
"Tactile Systems Technology, Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock MINNEAPOLIS, Minn.—— Feb. 23, 2023— Tactile Systems Technology, Inc. , a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $13.00 per share. The gross proceeds to Tactile Medical from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $32.5 million. Additionally, Tactile Medical has granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public o..."
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 6% stake in Tactile Systems Technology Inc.
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/26/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/23/2023 SC 13G/A MILLENNIUM MANAGEMENT LLC reports a 3.8% stake in TACTILE SYSTEMS TECHNOLOGY, INC.
01/23/2023 SC 13G/A BlackRock Inc. reports a 11.1% stake in TACTILE SYSTEMS TECHNOLOGY INC
01/18/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Tactile Medical Appoints Carmen Volkart to Board of Directors"
12/23/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "TACTILE SYSTEMS TECHNOLOGY, INC. AMENDED AND RESTATED BY - LAWS Effective: March 10, 2021 December 19, 2022 Article I OFFICES Section 1.1              REGISTERED OFFICE . The Corporation shall maintain a registered office and registered agent within the State of Delaware at such place within such State as may be designated from time to time by the B b oard of D d irectors of the Corporation. Section 1.2              OTHER OFFICES . The Corporation may also have offices in such other places, either within or without the State of Delaware, as the B b oard of D d irectors may from time to time designate or the business of the Corporation m..."
11/29/2022 8-K Quarterly results
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Third Quarter Revenue Increased 24% Year-Over-Year; First Nine Months Revenue Increased 18% Year-Over-Year MINNEAPOLIS, MN, November 7, 2022 – Tactile Systems Technology, Inc. , a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today reported financial results for the third quarter and nine months ended September 30, 2022. Third Quarter 2022 Summary: ● Total revenue increased 24% year-over-year to $65.3 million, compared to $52.5 million in third quarter 2021. ● Total revenue in third quarter 2022 included $11.0 million of revenue from sales of airway clearance products, which includes the AffloVest product line acquired on September 8, 2021, compared to $0.9 million of revenue in third qu..."
10/07/2022 SC 13G/A BlackRock Inc. reports a 10.4% stake in TACTILE SYSTEMS TECHNOLOGY INC
08/01/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/01/2022 8-K Quarterly results
Docs: "Second Quarter Revenue Increased 17% Year-Over-Year; First Half Revenue Increased 15% Year-Over-Year MINNEAPOLIS, MN, August 1, 2022 – Tactile Systems Technology, Inc. , a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today reported financial results for the second quarter and six months ended June 30, 2022. Second Quarter 2022 Summary: ● Total revenue increased 17% year-over-year to $59.6 million, compared to $51.1 million in second quarter 2021. ● Total revenue in second quarter 2022 included $8.0 million of revenue from sales of airway clearance products, which includes the AffloVest product line acquired on September 8, 2021. ● Operating loss of $4.1 million, compared to $0.1 m..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy